The brand drug industry is complaining about the drug-pricing deal’s Medicare price negotiation timeline that until recently only a few makers of biosimilars and generics complained about. However, the brand drug makers’ complaint is part of a tactic to kill the deal’s broader Medicare price negotiation provision, while makers of biosimilars and generics are lobbying to change the negotiation framework. Democrats’ pending reconciliation bill includes drug cost controls that would let Medicare negotiate prices after biopharmaceuticals have been on the...